Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children

J Pediatric Infect Dis Soc. 2022 Oct 25;11(10):459-462. doi: 10.1093/jpids/piac063.

Abstract

A birth cohort design was used to understand whether heterotypic ligand-blocking norovirus antibodies provide cross-protection within the GII genogroup. We found that almost one-half of children who experienced a norovirus GII episode had preexisting antibodies heterotypic to the infecting genotype; therefore, these antibodies did not provide cross-protection.

Keywords: Nicaragua; children; diarrhea; gastroenteritis; immunity; norovirus.

MeSH terms

  • Caliciviridae Infections* / prevention & control
  • Child
  • Child, Preschool
  • Feces
  • Gastroenteritis* / prevention & control
  • Genotype
  • Humans
  • Infant
  • Ligands
  • Norovirus* / genetics

Substances

  • Ligands